SR One
SR One is the corporate venture capital arm of GlaxoSmithKline.
Business Model:
Revenue: $11.4M
Employees: 2-10
Rankings
Industries / Tags:
Detailed SR One Information
Geographic Data
Address: 1 Broadway
City: Cambridge
State: MA
Zip: 02142
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$500M
Social
Linkedin
Crunchbase
Metrics
3,468,928Website Global Rank
4,128Website Monthly Traffic
Twitter Followers
Description
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Since 1985, SR One has invested approximately 800 million in more than 180 companies.
Contact Phone:
+16105671000
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2002 | Gryphon Therapeutics | Series B | 26M |
| 1/2005 | Predix Pharmaceuticals | Series C | 0 |
| 10/2015 | Decibel Therapeutics | Series A | 52M |
| 6/2007 | 7TM Pharma | Series D | 22M |
| 10/2007 | Altiris Therapeutics | Series B | 0 |
| 12/2014 | Avhana Health | Seed Round | 0 |
| 3/2005 | Novalar Pharmaceuticals | Series C | 27M |
| 1/2021 | River 2 Renal | Series A | 40M |
| 10/2019 | MiroBio | Series A | 33.2M |
| 1/2005 | OctoPlus | Series B | 23.9M |
| 1/1999 | Lexicon Pharmaceuticals | Post-IPO Equity | 0 |
| 6/2022 | Ancora Biotech LLC | Series A | 60M |
| 2/2016 | Spero Therapeutics | Series B | 30M |
| 5/2020 | HotSpot Therapeutics | Series B | 65M |
| 6/2022 | MiroBio | Series B | 0 |
| 3/2015 | Zikani Therapeutics | Series A | 22M |
| 3/2017 | Pulmocide | Series B | 30.4M |
| 5/2021 | Pulmocide | Series C | 0 |
| 4/2014 | Principia Biopharma | Series B | 50M |
| 1/2018 | Pandion Therapeutics | Series A | 58M |
| 8/2015 | Principia Biopharma | Series B | 15.3M |
| 12/2021 | Odyssey Therapeutics | Series A | 0 |
| 11/2020 | Decibel Therapeutics | Series D | 82.2M |
| 7/2014 | Atox Bio | Series E | 23M |
| 5/1999 | Xenogen Corporation | Series D | 11M |
| 6/2015 | Spero Therapeutics | Series A | 0 |
| 5/2017 | Turning Point Therapeutics | Series C | 45M |
| 1/2012 | Translate Bio | Series A | 20.7M |
| 5/2013 | Effector Therapeutics | Series A | 45M |
| 11/2007 | Novalar Pharmaceuticals | Series D | 30M |
| 6/2006 | Melinta Therapeutics | Series C | 0 |
| 11/2010 | Syntaxin | Series C | 29M |
| 4/2014 | Alios BioPharma | Series B | 41M |
| 5/2014 | Puridify | Seed Round | 1.4M |
| 2/2016 | MISSION Therapeutics | Series C | 86.5M |
| 5/2015 | Akamis Bio | Series C | 38.8M |
| 4/2014 | Spero Therapeutics | Series A | 0 |
| 12/2013 | VHSquared | Series A | - |
| 11/2000 | Onyvax | Venture Round | 14.9M |
| 12/1997 | Onyvax | Venture Round | - |
| 5/2006 | Onyvax | Series C | 14.9M |
| 9/2022 | Nimbus Therapeutics | Venture Round | 0 |
| 1/2009 | CalciMedica | Series C | 4M |
| 1/2022 | Simcha Therapeutics | Series B | 40M |
| 8/2016 | Tioma Therapeutics | Series A | 86M |
| 11/2003 | Protein Forest | Series A | 19M |
| 12/2021 | Nomic Bio | Series A | 17M |
| 1/2002 | Melinta Therapeutics | Series A | 22M |
| 5/2018 | Propeller Health | Series D | 20M |
| 1/1999 | Message Pharmaceuticals | Venture Round | 6.3M |
| 8/2005 | Protez Pharmaceuticals | Series B | 15M |
| 12/2017 | Atox Bio | Series F | 0 |
| 2/2007 | Locus Pharmaceuticals | Series E | 30.2M |
| 7/2015 | Translate Bio | Series B | 0 |
| 6/2022 | Mineralys Therapeutics | Series B | 0 |
| 12/2003 | Linguagen | Series A | 2M |
| 3/2020 | Design Therapeutics | Series A | 45.5M |
| 4/2015 | ZappRx | Series A | 14M |
| 10/2016 | Propeller Health | Series C | 21.5M |
| 4/2011 | F-Star Therapeutics | Venture Round | 0 |
| 10/2007 | Syntaxin | Series B | 32M |
| 9/2006 | Addex Therapeutics | Series C | 0 |
| 6/2014 | Navitor Pharmaceuticals | Series A | 23.5M |
| 4/2015 | True North Therapeutics | Series B | 35M |
| 1/2008 | POINT Biomedical | Private Equity Round | 0 |
| 12/2012 | Bicycle Therapeutics | Venture Round | 6M |
| 10/2019 | Arcellx | Series B | 0 |
| 9/2003 | Conforma Therapeutics | Series C | 30M |
| 10/2012 | Principia Biopharma | Series A | 12.5M |
| 1/2009 | Melinta Therapeutics | Series D | 0 |
| 6/2009 | Aileron Therapeutics | Series D | 40M |
| 11/2012 | Applied Genetics Technologies Corporation | Series B | 0 |
| 9/2019 | Nkarta Therapeutics | Series B | 114M |
| 4/2020 | Pandion Therapeutics | Series B | 80M |
| 9/2020 | Palleon Pharmaceuticals | Series B | 100M |
| 6/2018 | Decibel Therapeutics | Series C | 55M |
| 6/2004 | Nucleonics | Series B | 49.2M |
| 9/2007 | Novalar Pharmaceuticals | Series D | 30M |
| 9/2012 | IlluminOss Medical | Series C | 0 |
| 6/2018 | Nimbus Therapeutics | Series B | 65M |
| 10/2013 | F-Star Therapeutics | Series A | 0 |
| 1/2017 | Translate Bio | Series C | 51M |
| 2/2002 | Avantium | Venture Round | 0 |
| 10/2001 | Therion Biologics | Venture Round | 0 |
| 9/2021 | ADARx Pharmaceuticals | Series B | 75M |
| 9/2003 | Therion Biologics | Venture Round | 0 |
| 5/2000 | Xenogen Corporation | Series E | 30.6M |
| 10/2006 | Morphotek | Series D | 0 |
| 12/2009 | Genocea Biosciences | Series B | 25.7M |
| 7/2013 | Dicerna Pharmaceuticals | Series C | 0 |
| 11/2009 | Trinity Biosystems | Debt Financing | 7.5M |
| 10/2014 | Bicycle Therapeutics | Series A | 32M |
| 12/2012 | River Vision Development | Series A | 17M |
| 5/2021 | BioTheryX | Series E | 92M |
| 10/2016 | True North Therapeutics | Series D | 45M |
| 1/2014 | ZappRx | Seed Round | 1M |
| 10/2020 | Dren Bio | Series A | 0 |
| 5/2009 | Bird Rock Bio | Series A | 13M |
| 6/2017 | Bicycle Therapeutics | Series B | 52M |
| 9/2018 | Morphic Therapeutic | Series B | 0 |
| 12/2010 | Semprus BioSciences | Series B | 18M |
| 9/2005 | Algeta | Series A | 28.9M |
| 6/2015 | Gladius Pharmaceuticals | Series A | 3.3M |
| 3/2015 | Thrasos | Series D | 21M |
| 10/2012 | Thrasos | Series C | 35M |
| 10/2014 | Aileron Therapeutics | Series E | 33M |
| 10/2012 | Genocea Biosciences | Series C | 30M |
| 10/2014 | Atopix Therapeutics | Series A | 0 |
| 10/2017 | Palleon Pharmaceuticals | Series A | 47.6M |
| 1/2011 | Genocea Biosciences | Series B | 35M |
| 12/2015 | Navitor Pharmaceuticals | Series B | 33M |
| 12/2015 | Effector Therapeutics | Series B | 40M |
| 4/2015 | CRISPR Therapeutics | Series A | 35M |
| 12/2005 | Hypnion | Series B | 0 |
| 4/2015 | CRISPR Therapeutics | Series B | 29M |
| 8/2006 | Cabrellis Pharmaceuticals | Series A | 27.5M |
| 8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
| 7/2017 | Effector Therapeutics | Series C | 38.6M |
| 7/2011 | HTG Molecular Diagnostics | Series D | 0 |
| 9/2020 | Fore Biotherapeutics | Series C | 57M |
| 5/2010 | Ntprx | Series B | 43M |
| 11/2010 | iPierian | Series B | 29M |
| 7/2016 | Progyny | Series B | 14.7M |
| 5/2017 | Progyny | Series B | 10M |
| 9/2013 | iPierian | Venture Round | 30M |
| 12/2015 | True North Therapeutics | Series C | 40M |
| 1/2021 | Design Therapeutics | Series B | 125M |
| 8/2021 | ARS Pharmaceuticals | Series D | 55M |
| 4/2018 | Constellation Pharmaceuticals | Series F | 0 |
| 10/2018 | Turning Point Therapeutics | Equity | 80M |
| 11/2013 | MISSION Therapeutics | Series B | 32.2M |
| 1/2023 | ADARx Pharmaceuticals | Series B | 0 |
| 11/2022 | Rezo | Series A | 0 |
| 11/2021 | HotSpot Therapeutics | Series C | 0 |
| 8/2011 | MISSION Therapeutics | Series A | 6M |
| 1/2021 | River 3 Renal | Series A | 40M |
| 12/2022 | Pulmocide | Series C | 0 |
| 3/2015 | Nimbus Therapeutics | Series B | 43M |
| 4/2010 | Bicycle Therapeutics | Seed Round | - |
| 11/2006 | PharmaKodex | Series A | 13.5M |
| 7/2008 | NuPathe | Series B | 30M |
| 4/2018 | Zikani Therapeutics | Venture Round | 0 |
| 9/2015 | Asceneuron | Series A | 30.8M |
| 8/1998 | MicroMass Communications | Venture Round | 7M |
| 6/2016 | Morphic Therapeutic | Series A | 0 |
| 6/2009 | Anaphore | Series A | 13M |
| 6/2022 | Dren Bio | Series B | 0 |
| 3/2014 | Bird Rock Bio | Series B | 0 |
| 8/2006 | Ablynx | Series C | 50M |
| 7/2020 | Tranquis Therapeutics | Series A | 30M |
| 3/2003 | Hypnion | Series B | 47.5M |
| 1/2013 | Aileron Therapeutics | Series D | 12M |
| 4/2017 | ZappRx | Series B | 25M |
| 1/2015 | Nkarta Therapeutics | Series A | 11M |
| 10/2010 | Dicerna Pharmaceuticals | Series B | 4M |
| 3/2017 | Spero Therapeutics | Series C | 51.7M |
| 11/2013 | Aileron Therapeutics | Series E | 30M |
| 7/2020 | MISSION Therapeutics | Venture Round | 15M |
| 2/2009 | Genocea Biosciences | Series A | 23M |
| 7/2012 | Akamis Bio | Series B | 34.1M |
| 6/2014 | True North Therapeutics | Series A | 22M |
| 7/2007 | CalciMedica | Series A | 1.5M |
| 3/2003 | Alere | Venture Round | 5.1M |
| 10/2015 | Puridify | Series A | 3.4M |
| 11/2020 | F-Star Therapeutics | Post-IPO Equity | 0 |
| 10/2022 | Odyssey Therapeutics | Series B | 0 |
| 10/2016 | Bicycle Therapeutics | Series A | - |
| 11/1999 | Physician Verification Services | Venture Round | - |
| 2/2002 | Nucleonics | Series A | 1.6M |
| 4/2016 | Second Genome | Series B | 51M |
| 1/2009 | 7TM Pharma | Venture Round | 0 |
| 12/2009 | CalciMedica | Series C | 12M |
| 6/2011 | Nimbus Therapeutics | Series A | 24M |
| 6/2010 | Constellation Pharmaceuticals | Series B | 22.3M |
| 6/2011 | Constellation Pharmaceuticals | Series B | 15M |
| 10/2018 | Gotham Therapeutics | Series A | 54M |
| 6/2022 | MiroBio | Series B | 0 |
| 6/2022 | Ancora Biotech LLC | Series A | 0 |
| 6/2022 | Dren Bio | Series B | 0 |
| 6/2022 | Mineralys Therapeutics | Series B | 0 |
| 1/2022 | Simcha Therapeutics | Series B | 0 |
| 12/2021 | nplex biosciences | Series A | 0 |
| 12/2021 | Odyssey Therapeutics | Series A | 0 |
| 11/2021 | HotSpot Therapeutics | Series C | 0 |
| 9/2021 | ADARx Pharmaceuticals | Series B | 0 |
| 8/2021 | ARS Pharmaceuticals | Series D | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
